


# Discovery of a new vehicle peptide opens up a drug delivery route

22 June 2018



Cyclic decapeptide, which mimics the dimerization arm of the EGF receptor (EGFR), was previously found to be captured into cells. The authors have found the promising potential of this peptide as an intracellular delivery vehicle directed to EGFR-positive cells. The cellular delivery of the proapoptotic domain (PAD) peptide was challenged by conjugation with the above cyclic peptide. The cellular uptake of the conjugated peptide, which was composed of the cyclic peptide, the PAD peptide and a linker cleavable with a protease, was evaluated by treatment of EGFR-positive cells. Significant suppression of proliferation by the conjugated peptide was shown in a cell viability assay. Credit: Department of Medicinal Chemistry, TMDU

In the field of anticancer therapeutics, cationic antimicrobial peptides (AMPs) have gained prominence because of their cytotoxic and anticancer activity in drug-resistant cancer cells. Peptides are compounds consisting of two or more amino acids linked in a chain.

A membrane impermeable proapoptotic domain (PAD) peptide [KLAKLAK]<sub>2</sub> is known to be an antimicrobial agent and to cause mitochondrial membrane disruption, followed by cell death. Most AMPs including PAD have antitumor functions because of a multifunctional host defense system of multicellular organisms; however, they cannot penetrate cell membranes, and alone, they have

little cytotoxicity.

Previous studies have shown PAD peptides entering [cells](#) by their conjugation with cell-penetrating peptides (CPPs). A team of Tokyo Medical and Dental University (TMDU) researchers has shown a cyclic decapeptide, termed peptide 1, mimics the dimerization arm of the EGF receptor (EGFR). EGFR is involved in cellular signal transductions and cancer progression, and is overexpressed in many cancer cells. Hence, binding of peptide 1 to EGFR could potentially retard cancer growth.

In its latest study, the team aimed to verify the selectivity of peptide 1 to EGFR and investigated its efficacy as a vehicle for intracellular delivery to cells. The researchers reported their study in *Bioconjugate Chemistry*.

"As a proof-of-concept study, the cellular delivery of the PAD peptide was challenged by conjugation with peptide 1," study first author Kei Toyama explains. "The cellular uptake of a conjugated peptide 2, composed of peptide 1, the PAD peptide, and a linker cleavable with a protease, was evaluated by treatment of an EGFR-positive lung [cancer](#) cell line."

Significant suppression of proliferation by peptide 2 was observed in cell viability assays, whereas conjugate 3, which does not contain peptide 1, had no significantly inhibitory activity in the cell lines. Notably, the PAD peptide alone had no effect on the cells.

"Our findings suggest peptide 1 is a promising lead compound as a new intracellular delivery vehicle for therapeutically effective [peptides](#)," senior author Hirokazu Tamamura says. "Also, conjugate 2, with its apoptosis induction activity, can be explored as a new apoptotic peptide that could contribute to the development of anticancer reagents based on the AMP functions."

**More information:** Kei Toyama et al, Delivery of a Proapoptotic Peptide to EGFR-Positive Cancer Cells by a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR, *Bioconjugate Chemistry* (2018). DOI: [10.1021/acs.bioconjchem.8b00250](https://doi.org/10.1021/acs.bioconjchem.8b00250)

Provided by Tokyo Medical and Dental University  
APA citation: Discovery of a new vehicle peptide opens up a drug delivery route (2018, June 22) retrieved 24 November 2020 from <https://phys.org/news/2018-06-discovery-vehicle-peptide-drug-delivery.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*